NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Survivorship

Vanderbilt to Begin Testing Next Generation Device

BRISBANE, Australia and CARLSBAD, Calif., July 18, 2016 /PRNewswire/ — ImpediMed Limited (ASX:IPD) announces that it is partnering with Vanderbilt University for a series of patient and clinician human factors testing for the company’s next generation technology platform. Testing is expected to conclude by end of September 2016.

Under the direction of Principal Investigator Sheila H. Ridner, PhD, FAAN, researchers at the Vanderbilt University School of Nursing will test the innovative hardware design and software user interfaces of ImpediMed’s latest bioimpedance spectroscopy (BIS) technology platform for both patients and clinicians.

The Vanderbilt team of research professionals will observe product usage in specially designed labs and one-on-one interview settings. The university’s unique ability to recreate the user experience in both clinical and at-home settings makes it an ideal partner for this project.

“As a longtime user of BIS technology in my research, I am excited about the potential of this next generation device to empower not only clinicians, but also patients, to more easily monitor their health status,” said Ridner, who also holds the Martha Rivers Ingram Chair in Nursing at Vanderbilt.

The Vanderbilt University School of Nursing is a leader in developing and testing innovations in nursing practice, research and education. It is part of Vanderbilt University, an independent, privately supported university ranked among the top 20 research and academic universities in the United States.

“We are pleased to continue our clinical relationship with an institution as prestigious as Vanderbilt University,” said Richard Carreon, Managing Director and CEO of ImpediMed. “With our next generation product, our goal is to drive innovation in precision medicine by delivering actionable, and clinically relevant data.”

About ImpediMed

Founded and headquartered in Brisbane, Australia with U.S. offices in Carlsbad, Calif., and Bloomington, Minn., ImpediMed is the world leader in the development and distribution of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the noninvasive clinical assessment and monitoring of fluid status in patients. ImpediMed has the first medical device with FDA clearance in the U.S. to aid healthcare professionals to clinically assess secondary unilateral lymphedema of the arm and leg in women and the leg in men.

For additional information, visit